Abstract
Advancing Sickle Cell Disease Treatment: Addressing Access Challenges
In this editorial, we discuss the recent approval by the U.S. Food and Drug Administration (FDA) of two new treatments, Casgevy and Lyfgenia, for sickle cell disease (SCD) in patients aged 12 and older. These treatments are significant because Casgevy is the first FDA-approved therapy to use a new genome editing technology. This approval represents a big step forward in gene therapy and in the treatment of sickle cell disease which is clinically characterised by the complications of an unresponsive hemoglobin. However, while celebrating this achievement, we need to think about how to make sure everyone who needs these treatments can get them, especially in Africa where SCD affects many people. It's not just about making the treatments, but also about making sure they reach the people who need them the most. This means we need to work on things like logistics (how to get the treatments to the right places) and political will (making sure governments support getting these treatments to everyone who needs them). In the end, it's not enough to have these new treatments available - we need to make sure they actually help the people who need them most, wherever they are in the world.
Dear Editor,
I am writing to bring to your keen attention, a remarkable milestone in the field of gene therapy and hematology, particularly the recent approval by the US Food and Drug Administration (FDA) of two groundbreaking treatments, Casgevy and Lyfgenia, for the management of sickle cell disease (SCD) in patients aged 12 and older. 1
Introduction
The approval of these cell-based gene therapies marks a historic moment in the trajectory of SCD treatment. These therapies work by reprogramming the patient's own cells to produce a form of hemoglobin that resists sickling, thereby significantly reducing the clinical severity of the disease. Notably, CASGEVY (known generically as Exagamglogene autotemcel) a CRISPR/Cas9 gene-edited therapy, 2 has now been approved for certain eligible patients with SCD or transfusion-dependent beta thalassemia1,3 thus standing out as the first FDA-approved innovative therapy utilizing a novel genome editing technology for hemoglobinopathies. 3
In the same vein, LYFGENIA (known generically as Lovotibeglogene autotemcel), a lentiviral gene therapy has been approved for the treatment of sickle cell disease. 4
The utilization of Casgevy and Lyfgenia's cutting-edge genome editing technology signifies a pivotal advancement in modern medicine and the incorporation of such novel techniques not only enhances treatment efficacy but also opens new avenues for exploring precision medicine in hematological disorders. 5
Global Health Considerations
SCD is a global health concern, and the approval of these therapies brings with it a responsibility to foster international collaboration. Sharing knowledge, resources, and facilitating technology transfer will be instrumental in extending the benefits of these treatments to regions with limited access to advanced healthcare and constrained resources.
Implications for Sickle Cell Disease Management
SCD is a significant public health burden in Africa, a continent with the highest prevalence of the sickle cell trait, with figures suggesting that between 10% and 40% of the entire population may be affected with the disorder. 6
Estimates suggest that 4.4 million people have SCD worldwide, while about 43 million are living with sickle cell trait with Nigeria having bearing the bulk of affected populations. 6
With the disease disproportionately affecting African countries and a host of several other low and middle income countries, the approval of these therapies underscores the urgency of addressing health disparities. The potential impact on patients’ quality of life, particularly in regions where SCD is prevalent, cannot be overstated.
It is worthy of note and considerate however to state the slow but steady success of implementing newborn screening for SCD, stroke screening, and use of hydroxyurea in African countries. 7 Additionally, hematopoietic stem cell transplantation has also been in use in some African countries despite the similar high costs and medical complexity to gene therapies. 8 Therefore, more synergy, comparative analysis and evaluation need to be done to make an exponential impact if gene therapy is to be added to the picture.
Equitable Access Challenges
While celebrating this scientific triumph, it is crucial to acknowledge the challenges ahead. Ensuring equitable access to Casgevy and Lyfgenia, especially for African patients who bear a disproportionate burden of SCD, necessitates a concerted effort in logistics, infrastructure, and political will.
In a nutshell, the challenge in its entirety lingers on how these new treatment modalities can get adequate finance either through subsides or aids and get access to Africa, the developing world market where the poverty rate stands at around 50% among the rural population and over 10% in urban areas. 9
Call to Action
Modern Medicine, through CRISPR-based therapy has witnessed a relieving miracle, one that's definitely destined to change the face and perception of pharmacotherapy forever, portending potential cures for chronic genetic diseases beyond SCD.
This correspondence encourages the scientific community, policymakers, and healthcare practitioners to collaborate in devising strategies that prioritize equitable distribution and accessibility of these innovative therapies. Concerted efforts are needed to bridge the gap between scientific breakthroughs and their real-world impact, particularly in regions where the burden of SCD is most pronounced, which unfortunately are grossly impoverished and unable to afford the current market values of Casgevy and Lyfgenia (currently 2.2 and 3.1 million USD, respectively). 10
In conclusion, the FDA's approval of Casgevy and Lyfgenia represents a great breakthrough triumph in the ongoing quest for effective SCD treatments. However, the true measure of success lies in the ability to translate these advancements into tangible improvements in the lives of those affected, particularly in regions where the need is most strikingly acute.
